3 unknown. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Unknown 3 |
| Phase 1 | 1 | Unknown 1 |
Follow GVHD: new trials by email Literature Review of GVHD trials Research Report on GVHD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prophylaxis of Graft-versus-host Disease With Anti-CD25 Antibody in Patients Underwent HSCT CD25 treatment, low-dose ATG - GVHD | Phase 2 | Unknown | Wang Xin | 40 | 2024-03-26 | 2024-03-28 |
| MAP-guided Preemptive Therapy of aGvHD by Ruxolitinib Ruxolitinib - GVHD, Acute Stem Cell Transplant Complications | Phase 2 | Unknown | Sichuan University | 62 | 2023-10-01 | 2023-10-10 |
| Umbilical Cord Blood-derived Mesenchymal Stem Cells for the Treatment of Steroid-refractory Acute or Chronic Graft-versus-host-disease Human umbilical cord blood-derived mesenchymal stem cells - Graft-Versus-Host Disease, GVHD | Phase 1 / Phase 2 | Unknown | Samsung Medical Center | 30 | 2012-01-01 | 2012-03-16 |
ruxolitinib (1)
Samsung Medical Center (1) · Sichuan University (1) · Wang Xin (1)
China (2) · South Korea (1)
Xin Wang (1)